Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 01, 2024 11:37am

77 Views

Post# 36158357

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

August 01, 2024 - Biogen's CEO suggestion today that he’s open to more risky, less validated technologies represents a shift in thinking.

As for what Biogen might be interested in buying or dealing with, the CEO said that the company is already “long on neuroscience,” so areas like immunology or rare diseases might be more appealing.

Biogen picked Reata up for $7.3 billion in July 2023, bringing in the approved medicine Skyclarys for Friedreich’s ataxia.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"